<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="618">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 27, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00175851</url>
  </required_header>
  <id_info>
    <org_study_id>N01197</org_study_id>
    <secondary_id>Not yet available</secondary_id>
    <nct_id>NCT00175851</nct_id>
  </id_info>
  <brief_title>Open Label Trial to Study the Long-term Safety and Efficacy of Seletracetam for the Treatment of Epilepsy</brief_title>
  <official_title>An Open-label, Multicenter, Follow-up Trial to Evaluate the Long-term Safety and Efficacy of Seletracetam Used as Adjunctive Treatment Using a Flexible Dosing Scheme of 4 to 80 mg b.i.d. in Subjects Aged 16 Years or Older Suffering From Epilepsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCB Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UCB Pharma</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Canada: Health Canada</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a safety and efficacy study of add-on therapy with seletracetam in epilepsy patients
      who have participated in a previous seletracetam study
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>May 2008</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Safety profile of seletracetam</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction in seizure frequency</measure>
  </secondary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Epilepsy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Seletracetam (ucb 44212)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A signed and dated IRB/IEC approved written informed consent form

          -  Male/female age 18 years (16 years where permitted) to 65 years

          -  Minimum body weight of 40 kg

          -  Patients having participated in a previous seletracetam study

          -  Female patients without childbearing potential or using a medically accepted
             non-hormonal contraceptive method are eligible.

        Exclusion Criteria:

          -  Ongoing psychiatric disease other than mild controlled disorders

          -  Subject with clinically significant abnormalities in laboratory tests or ECG

          -  Poor compliance with visit schedule or medication intake in a previous seletracetam
             study

          -  Subject taking part in another clinical/pharmacological study, with the exception of
             seletracetam studies, in the 30 days preceding enrollment
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Barbara Bennett, PhD</last_name>
    <role>Study Director</role>
    <affiliation>UCB Pharma</affiliation>
  </overall_official>
  <verification_date>May 2012</verification_date>
  <lastchanged_date>May 25, 2012</lastchanged_date>
  <firstreceived_date>September 9, 2005</firstreceived_date>
  <responsible_party>
    <name_title>Study Director</name_title>
    <organization>UCB</organization>
  </responsible_party>
  <keyword>Partial onset, primary generalized seizures, seletracetam</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Epilepsy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
